TransCode Therapeutics
RNAZ
4 hedge funds and large institutions have $284K invested in TransCode Therapeutics in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and 5 closing their positions.
170% more capital invested
Capital invested by funds: $105K → $284K (+$179K)
0.01% more ownership
Funds ownership: 0% → 0.01% (+0.01%)
20% less funds holding
Funds holding: 5 → 4 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$506K |
| 2 |
VF
Virtu Financial
New York
|
+$83.8K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$33.5K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.99K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$46.5K |
| 2 |
Renaissance Technologies
New York
|
-$31K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$8.61K |
| 4 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$8.24K |
| 5 |
HF
HRT Financial
New York
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $229K | +$506K | +362 | New |
|
|
VF
2
Virtu Financial
New York
| $37K | +$83.8K | +60 | New |
|
|
TSS
3
Two Sigma Securities
New York
| $15K | +$33.5K | +24 | New |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $3.37K | +$6.99K | +5 | New |
|
5
Wells Fargo
San Francisco,
California
| $3 | – | – | – |
|
|
FPFS
6
First Personal Financial Services
Charlotte,
North Carolina
| $1 | – | – | – |
|
|
7
Citadel Advisors
Miami,
Florida
| – | -$46.5K | -8 | Closed |
|
|
8
Renaissance Technologies
New York
| – | -$31K | -5 | Closed |
|
|
9
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$8.24K | -1 | Closed |
|
|
10
Geode Capital Management
Boston,
Massachusetts
| – | -$8.61K | -1 | Closed |
|
|
HF
11
HRT Financial
New York
| – | -$5K | -1 | Closed |
|
12
Bank of America
Charlotte,
North Carolina
| – | -$266 | – | – |
|
13
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$1.81K | – | – |
|
14
UBS Group
Zurich,
Switzerland
| – | -$1.3K | – | – |
|
|
XT
15
XTX Topco
George Town,
Cayman Islands
| – | -$1.77K | – | – |
|
RNAZ Hedge Fund Activity: Q1 2024 in Review
4 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in TransCode Therapeutics (RNAZ) for Q1 2024, worth a combined $284K — up 170% from $105K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of RNAZ and 4 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $506K. The largest seller was Citadel Advisors, exiting entirely with an estimated $46.5K sold.
- 4 institutional investors held TransCode Therapeutics (RNAZ) as of Q1 2024, down from 5 in Q4 2023.
- Funds reported $284K of TransCode Therapeutics stock for Q1 2024, up 170% quarter-over-quarter.
- 4 funds opened new TransCode Therapeutics positions in Q1 2024 and 5 closed out, a net change of -1 holder.
- The largest TransCode Therapeutics buyer in Q1 2024 was Sabby Management, an estimated $506K added.
- The largest TransCode Therapeutics seller in Q1 2024 was Citadel Advisors, an estimated $46.5K sold.
Based on aggregated 13F filings for Q1 2024.